Avid Bioservices Inc (CDMO)

[jakedogman1]

agree.... when a $1.3 mil "miss" on earnings due to a one time severance payout causes a $100 mil plus drop in market cap (22% change in value on one day), mgmt can't make a claim that the IP is not material to the value of the company. Particularly when Merck has three ongoing trials with bavituximab which are all phase 2. In addition Oncologie bought the rights to varisacumab (r84) from Avid:

https://oncologie.international/our-pipeline/varisacumab/

In addition to the $95 mil, Avid can get up to $21 mil in milestones from r84 drug and royalties as well.

From annual report:

I cannot find any PR in Sept or Oct 2018 mentioning sale of r84...

http://ir.avidbio.com/static-files/62a843b4-8779-47fa-91c2-75fbcae06828

As a result of the sale of our r84 and PS-targeting technologies in September 2018 and February 2018, respectively (as described in Note 10 to the
accompanying consolidated financial statements), the abandonment of our remaining research and development assets, and the strategic shift in our corporate
direction to focus solely on our CDMO business, the operating results of our former research and development segment have been excluded from continuing
operations and reported as income (loss) from discontinued operations, net of tax, in the accompanying consolidated financial statements for all periods
presented. The gains of $1,000 and $8,000, respectively, which were recorded in connection with the aforementioned sales of our r84 and PS-targeting
technologies, which are included in income (loss) from discontinued operations, net of tax, in the accompanying Consolidated Statements of Operations and
Comprehensive Loss for the fiscal years ended April 30, 2019 and 2018, respectively.